ATE164395T1
(de)
*
|
1990-12-03 |
1998-04-15 |
Genentech Inc |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
US6696251B1
(en)
|
1996-05-31 |
2004-02-24 |
Board Of Trustees Of The University Of Illinois |
Yeast cell surface display of proteins and uses thereof
|
CA2338865A1
(en)
*
|
1997-07-29 |
1999-02-11 |
James S. Huston |
Methods for detecting binding events using multiple binding partners and muliple targets
|
DE19802576B4
(de)
*
|
1998-01-23 |
2004-10-28 |
Xerion Pharmaceuticals Ag |
Verfahren zur gleichzeitigen Identifizierung von Proteinen und ihren Bindungspartnern
|
EP1100890A2
(de)
|
1998-07-27 |
2001-05-23 |
Genentech, Inc. |
Verbesserung der transformationseffizienz in phagendisplay durch abänderung des hüllproteins
|
SI2319928T1
(sl)
|
1998-10-23 |
2013-08-30 |
Kirin-Amgen, Inc. |
Dimerni trombopoietinski peptidni mimetiki, ki se veĺ˝ejo na receptor mp1 in imajo trombopoietinsko aktivnost
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US7488590B2
(en)
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
AU770952B2
(en)
|
1999-03-01 |
2004-03-11 |
Genentech Inc. |
Antibodies for cancer therapy and diagnosis
|
WO2000061790A1
(en)
*
|
1999-04-14 |
2000-10-19 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High sensitivity phage display biomolecule detection
|
AU773957C
(en)
*
|
1999-05-14 |
2005-08-25 |
Georges, Elias Ph.D. |
Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction
|
EP1684077A1
(de)
*
|
1999-05-14 |
2006-07-26 |
McGill University |
Verfahren zur Identifizierung von Modulatoren wechselwirkender Proteine
|
US20030086902A1
(en)
*
|
1999-12-27 |
2003-05-08 |
Atsushi Sato |
Cytokine-like peptide
|
EP1273918B1
(de)
*
|
1999-12-27 |
2008-02-20 |
Crucell Holland B.V. |
Antikörper gegen Ep-Cam
|
DE10009341A1
(de)
*
|
2000-02-22 |
2001-09-06 |
Florian Kern |
Verfahren zur antigen-spezifischen Stimulation von T-Lymphozyten
|
SE0000597D0
(sv)
*
|
2000-02-24 |
2000-02-24 |
Active Biotech Ab |
Novel antibody
|
EP1130099A1
(de)
*
|
2000-02-25 |
2001-09-05 |
Crucell Holland B.V. |
Aktiviertes Vitronektin als Angiogenesemarker nachgewiesen durch Phagen-Antikörper
|
IL151389A0
(en)
*
|
2000-02-25 |
2003-04-10 |
Crucell Holland Bv |
Activated vitronectin as a marker of angiogenesis detected with phage antibodies
|
DK2857516T3
(en)
|
2000-04-11 |
2017-08-07 |
Genentech Inc |
Multivalent antibodies and uses thereof
|
JP2003530870A
(ja)
|
2000-04-21 |
2003-10-21 |
アムジエン・インコーポレーテツド |
Apo−AI/AIIペプチド誘導体
|
US6677136B2
(en)
|
2000-05-03 |
2004-01-13 |
Amgen Inc. |
Glucagon antagonists
|
EP1174440A1
(de)
*
|
2000-07-19 |
2002-01-23 |
U-BISys B.V. |
Ein selektiv exprimiertes Epitop auf das menschliches CD38 Molekül detektiert von einem "phage display library"-derivierten menschlichen scFv Antikörperfragment
|
CA2415473A1
(en)
|
2000-07-27 |
2002-02-07 |
Genentech, Inc. |
Apo-2l receptor agonist and cpt-11 synergism
|
FR2821856B1
(fr)
*
|
2001-03-09 |
2003-12-26 |
Didier Elmlinger |
Procede de criblage croise d'une banque d'expression d'adn et d'une banque de molecules cibles isolees sur un support permettant la comparaison simultanee de l'affinite et la selectivite de leurs interactions
|
EP1921088B1
(de)
|
2001-05-11 |
2014-10-08 |
Amgen Inc. |
Peptide und damit zusammenhängende an Tall-1 bindende Moleküle
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
ES2372321T3
(es)
|
2001-06-20 |
2012-01-18 |
Genentech, Inc. |
Composiciones y métodos para el diagnóstico y tratamiento de un tumor de pulmón.
|
WO2003008968A2
(en)
*
|
2001-07-19 |
2003-01-30 |
Signet Laboratories, Inc. |
Human tissue specific drug screening procedure
|
KR101008758B1
(ko)
|
2001-09-18 |
2011-01-14 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
US7332474B2
(en)
|
2001-10-11 |
2008-02-19 |
Amgen Inc. |
Peptides and related compounds having thrombopoietic activity
|
KR100623128B1
(ko)
|
2002-01-02 |
2006-09-14 |
제넨테크, 인크. |
종양의 진단 및 치료 방법 및 이를 위한 조성물
|
EP2011886A3
(de)
|
2002-04-16 |
2009-02-11 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
|
JP4753578B2
(ja)
|
2002-06-03 |
2011-08-24 |
ジェネンテック, インコーポレイテッド |
合成抗体ファージライブラリー
|
EP1525223B1
(de)
|
2002-06-13 |
2007-11-21 |
Crucell Holland B.V. |
Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
ES2368733T3
(es)
|
2002-07-18 |
2011-11-21 |
Merus B.V. |
Producción recombinante de mezclas de anticuerpos.
|
US6919426B2
(en)
|
2002-09-19 |
2005-07-19 |
Amgen Inc. |
Peptides and related molecules that modulate nerve growth factor activity
|
WO2004045532A2
(en)
|
2002-11-15 |
2004-06-03 |
Chiron Corporation |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
CA2527694C
(en)
|
2003-05-30 |
2015-07-14 |
Hendricus Renerus Jacobus Mattheus Hoogenboom |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
AU2004251890B2
(en)
|
2003-06-25 |
2010-09-23 |
Crucell Holland B.V. |
Binding molecules for the treatment of myeloid cell malignancies
|
NZ544317A
(en)
|
2003-07-08 |
2009-05-31 |
Genentech Inc |
IL-17 A/F heterologous polypeptides and therapeutic uses thereof
|
ES2472690T3
(es)
|
2003-11-17 |
2014-07-02 |
Genentech, Inc. |
Anticuerpo contra CD22 para el tratamiento de tumores de origen hematopoy�tico
|
CA2554054C
(en)
|
2004-01-20 |
2013-06-04 |
Merus B.V. |
Mixtures of binding proteins
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
NZ580607A
(en)
|
2004-05-27 |
2011-05-27 |
Crucell Holland Bv |
Binding molecules capable of neutralizing rabies virus and uses thereof
|
AU2011218688B2
(en)
*
|
2004-05-27 |
2013-01-10 |
Crucell Holland B.V. |
Binding molecules capable of neutralizing rabies virus and uses thereof
|
JP2008505928A
(ja)
|
2004-07-08 |
2008-02-28 |
アムジェン インコーポレーテッド |
治療用ペプチド
|
JP4991544B2
(ja)
|
2004-08-23 |
2012-08-01 |
イエダ リサーチ アンド デベロップメント カンパニー リミテッド |
ストレス応答を媒介するためのペプチド阻害剤
|
WO2006040322A1
(en)
|
2004-10-12 |
2006-04-20 |
Crucell Holland B.V. |
Binding molecules for treatment and detection of cancer
|
AU2005303758B2
(en)
|
2004-11-11 |
2011-04-28 |
Crucell Holland B.V. |
Compositions against SARS-coronavirus and uses thereof
|
US8022040B2
(en)
|
2004-11-29 |
2011-09-20 |
The Regents Of The University Of California |
Hydroxyapatite-binding peptides for bone growth and inhibition
|
AU2005318171B2
(en)
|
2004-12-20 |
2011-09-29 |
Crucell Holland B.V. |
Binding molecules capable of neutralizing West Nile virus and uses thereof
|
RU2007137489A
(ru)
|
2005-03-10 |
2009-04-20 |
Дженентек, Инк. (Us) |
Способы и композиции для модуляции целостности сосудов
|
EP1879921B1
(de)
|
2005-05-12 |
2011-04-27 |
Crucell Holland B.V. |
Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
WO2007031550A2
(en)
|
2005-09-15 |
2007-03-22 |
Crucell Holland B.V. |
Method for preparing immunoglobulin libraries
|
EP3037544A1
(de)
|
2005-10-13 |
2016-06-29 |
Human Genome Sciences, Inc. |
Verfahren und zusammensetzung zur verwendung bei der behandlung von systemisch lupus erythematosus patienten mit autoantikörper-positiven leiden
|
ATE485517T1
(de)
|
2006-03-22 |
2010-11-15 |
Viral Logic Systems Technology |
Verfahren zur identifizierung von polypeptid- targets
|
US8129334B2
(en)
|
2006-03-31 |
2012-03-06 |
The Regents Of The University Of California |
Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
|
WO2007126455A2
(en)
|
2006-04-05 |
2007-11-08 |
Genentech, Inc. |
Method for using boc/cdo to modulate hedgehog signaling
|
US9283260B2
(en)
|
2006-04-21 |
2016-03-15 |
Amgen Inc. |
Lyophilized therapeutic peptibody formulations
|
US8377448B2
(en)
|
2006-05-15 |
2013-02-19 |
The Board Of Trustees Of The Leland Standford Junior University |
CD47 related compositions and methods for treating immunological diseases and disorders
|
HUE027099T2
(hu)
|
2006-06-06 |
2016-08-29 |
Crucell Holland Bv |
Humán kötõmolekulák staphylococcus elleni ölõaktivitással és alkalmazásuk
|
CA2654502C
(en)
|
2006-06-06 |
2015-07-14 |
Crucell Holland B.V. |
Human binding molecules having killing activity against enterococci and uses thereof
|
US7981425B2
(en)
|
2006-06-19 |
2011-07-19 |
Amgen Inc. |
Thrombopoietic compounds
|
EP2520935A3
(de)
|
2006-08-09 |
2013-02-13 |
Homestead Clinical Corporation |
Organspezifische Proteine und Verfahren zu deren Verwendung
|
DK2450379T3
(da)
|
2006-09-07 |
2016-02-08 |
Crucell Holland Bv |
Humane bindingsmolekyler, der er i stand til at neutralisere influenzavirus h5n1, og anvendelser deraf
|
MY170607A
(en)
|
2006-09-07 |
2019-08-20 |
Crucell Holland Bv |
Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
|
EP2083017A4
(de)
|
2006-09-14 |
2011-01-12 |
Med & Biological Lab Co Ltd |
Antikörper mit verbesserter adcc-wirkung und verfahren zu dessen herstellung
|
WO2008068246A1
(en)
|
2006-12-05 |
2008-06-12 |
Crucell Holland B.V. |
Liquid anti-rabies antibody formulations
|
ES2379413T3
(es)
|
2007-02-22 |
2012-04-25 |
Genentech, Inc. |
Procedimientos para detectar la enfermedad inflamatoria del intestino
|
JP5754135B2
(ja)
|
2007-03-26 |
2015-07-29 |
アジェナス インコーポレイテッド |
関心対象のタンパク質の細胞表面ディスプレイ、スクリーニング、および産生
|
US9175078B2
(en)
|
2008-01-25 |
2015-11-03 |
Amgen Inc. |
Ferroportin antibodies and methods of use
|
MX2010011717A
(es)
|
2008-05-01 |
2010-11-30 |
Amgen Inc |
Anticuerpos anti-hepcidina y metodos de uso.
|
EP2319869B1
(de)
|
2008-06-20 |
2016-08-17 |
National University Corporation Okayama University |
ANTIKÖRPER GEGEN DEN OXIDIERTES LDL/ß²GPI-KOMPLEX UND ANWENDUNG DAVON
|
AU2009262199B2
(en)
|
2008-06-27 |
2012-08-09 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
US9182406B2
(en)
|
2008-08-04 |
2015-11-10 |
Biodesy, Inc. |
Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
|
MY183517A
(en)
|
2009-05-11 |
2021-02-24 |
Janssen Vaccines & Prevention Bv |
Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
|
CA2762837C
(en)
|
2009-05-20 |
2021-08-03 |
Novimmune S.A. |
Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
|
ES2564207T3
(es)
|
2009-10-22 |
2016-03-18 |
F. Hoffmann-La Roche Ag |
Métodos y composiciones para modular la activación con hepsina de la proteína estimuladora de macrófagos
|
EP3002297B1
(de)
|
2009-11-30 |
2020-04-08 |
F. Hoffmann-La Roche AG |
Antikörper zur behandlung und der diagnose slc34a2 (tat211) exprimierender tumore.
|
KR20130004579A
(ko)
|
2010-02-23 |
2013-01-11 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 조성물 및 방법
|
RU2636461C2
(ru)
|
2010-05-03 |
2017-11-23 |
Дженентек, Инк. |
Композиции и способы для диагностики и лечения опухоли
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
CA2827170A1
(en)
|
2011-02-11 |
2012-08-16 |
David M. Hilbert |
Monovalent and multivalent multispecific complexes and uses thereof
|
GB2503604B
(en)
|
2011-03-21 |
2020-04-22 |
Biodesy Llc |
Classification of kinase inhibitors using second harmonic optical techniques
|
EP2715350B1
(de)
|
2011-05-23 |
2017-09-27 |
Yeda Research and Development Co. Ltd. |
Verwendung einer akt-phosphorylierung als biomarker zur prognose neurodegenerativer erkrankungen und zu ihrer behandlung
|
WO2012162561A2
(en)
|
2011-05-24 |
2012-11-29 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
CN103906763B
(zh)
|
2011-07-14 |
2016-10-12 |
克鲁塞尔荷兰公司 |
能够中和系统发育群1和系统发育群2的a型流感病毒以及b型流感病毒的人结合分子
|
CA2846083A1
(en)
|
2011-09-15 |
2013-03-21 |
Genentech, Inc. |
Methods of promoting differentiation
|
WO2013056148A2
(en)
|
2011-10-15 |
2013-04-18 |
Genentech, Inc. |
Methods of using scd1 antagonists
|
CA2858099C
(en)
|
2011-12-22 |
2020-12-15 |
Glycomimetics, Inc. |
E-selectin antagonist compounds, compositions, and methods of use
|
WO2013109856A2
(en)
|
2012-01-18 |
2013-07-25 |
Genentech, Inc. |
Methods of using fgf19 modulators
|
JP6545959B2
(ja)
|
2012-02-11 |
2019-07-17 |
ジェネンテック, インコーポレイテッド |
Rスポンジン転位およびその使用方法
|
EP2825549B1
(de)
|
2012-03-16 |
2018-10-10 |
F. Hoffmann-La Roche SA |
Gleichmässig stabilisierte manipulierte proteine
|
MX2014010953A
(es)
|
2012-03-16 |
2014-10-13 |
Hoffmann La Roche |
Metodos para tratamiento de melanoma con inhibidores pak1.
|
US9139863B2
(en)
|
2012-03-16 |
2015-09-22 |
Genentech, Inc. |
Engineered conformationally-stabilized proteins
|
KR102382304B1
(ko)
|
2012-04-20 |
2022-04-04 |
메뤼스 엔.페. |
Ig-유사 분자의 제조방법 및 제조수단
|
JP6302460B2
(ja)
|
2012-04-25 |
2018-03-28 |
バイオデシー, インコーポレイテッド |
タンパク質のアロステリックモジュレーターを検出するための方法
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
WO2014089269A1
(en)
|
2012-12-07 |
2014-06-12 |
Glycomimetics, Inc. |
Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
JOP20140087B1
(ar)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
|
CA2907181C
(en)
|
2013-03-15 |
2023-10-17 |
Viktor Roschke |
Multivalent and monovalent multispecific complexes and their uses
|
MY176706A
(en)
|
2013-03-15 |
2020-08-19 |
Genentech Inc |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
CA3100140C
(en)
|
2014-01-28 |
2023-10-24 |
Buck Institute For Research On Aging |
Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
KR20170005016A
(ko)
|
2014-05-23 |
2017-01-11 |
제넨테크, 인크. |
MiT 바이오마커 및 그의 사용 방법
|
CN114057857A
(zh)
|
2014-06-20 |
2022-02-18 |
豪夫迈·罗氏有限公司 |
基于chagasin的支架组合物、方法和应用
|
WO2016106286A1
(en)
|
2014-12-23 |
2016-06-30 |
Biodesy, Inc. |
Attachment of proteins to interfaces for use in nonlinear optical detection
|
KR20180012747A
(ko)
|
2015-04-06 |
2018-02-06 |
서브도메인, 엘엘씨 |
드 노보 결합 도메인 함유 폴리펩티드 및 그의 용도
|
WO2016172485A2
(en)
|
2015-04-24 |
2016-10-27 |
Genentech, Inc. |
Multispecific antigen-binding proteins
|
WO2018049275A1
(en)
|
2016-09-09 |
2018-03-15 |
Genentech, Inc. |
Selective peptide inhibitors of frizzled
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
EP3615569A1
(de)
|
2017-04-25 |
2020-03-04 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antikörper und verfahren zur diagnose und behandlung von epstein-barr-virus-infektionen
|
EP3655430A1
(de)
|
2017-07-19 |
2020-05-27 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Antikörper und verfahren zur diagnose und behandlung von hepatitis-b-virusinfektionen
|
EP3897652A4
(de)
|
2018-12-20 |
2022-09-14 |
KSQ Therapeutics, Inc. |
Substituierte pyrazolopyrimidine und substituierte purine und ihre verwendung als inhibitoren der ubiquitin-specific-processing protease 1 (usp1)
|
JP7397884B2
(ja)
|
2019-05-09 |
2023-12-13 |
ジェネンテック, インコーポレイテッド |
抗体の作製方法
|
MX2023004937A
(es)
|
2020-10-30 |
2023-05-17 |
Ksq Therapeutics Inc |
Formas en estado solido de pirazolopirimidinas sustituidas y usos de estas.
|
WO2023066881A1
(en)
|
2021-10-18 |
2023-04-27 |
Astrazeneca Ab |
Inhibition of map3k15 for treating and preventing diabetes
|